ES2136290T3 - Metodo para separar componentes protectores de bordetella pertussis. - Google Patents

Metodo para separar componentes protectores de bordetella pertussis.

Info

Publication number
ES2136290T3
ES2136290T3 ES95917474T ES95917474T ES2136290T3 ES 2136290 T3 ES2136290 T3 ES 2136290T3 ES 95917474 T ES95917474 T ES 95917474T ES 95917474 T ES95917474 T ES 95917474T ES 2136290 T3 ES2136290 T3 ES 2136290T3
Authority
ES
Spain
Prior art keywords
bordetella pertussis
components
pertussis
protective
protective components
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95917474T
Other languages
English (en)
Inventor
Akihiro Suehara
Eiji Yamamoto
Shigeo Fujii
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Application granted granted Critical
Publication of ES2136290T3 publication Critical patent/ES2136290T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/32—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
    • C07K14/325—Bacillus thuringiensis crystal peptides, i.e. delta-endotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

PARA PROPORCIONAR UN METODO EFICIENTE DE SEPARACION DE COMPONENTES PROTECTORES DE BORDETELLA PERTUSSIS. EN BASE A LAS DIFERENCIAS DE ADSORBABILIDAD DEL GEL DE FOSFATO CALCICO FORMADO POR ADICION DE IONES CALCIO AL CULTIVO DE BORDETELLA PERTUSSIS EN PRESENCIA DE EXCESO DE IONES DE FOSFATO, LOS COMPONENTES PROTECTORES DE LA BORDETELLA PERTUSSIS SON SEPARADOS DEL CULTIVO DE BORDETELLA PERTUSSIS. TRADICIONALMENTE, LOS COMPUESTOS PROTECTORES DE LA BORDETELLA PERTUSSIS HAN SIDO SEPARADOS USANDO METODOS DE PURIFICACION DIFERENTES PARA LOS RESPECTIVOS COMPONENTES. DE ACUERDO CON LA PRESENTE INVENCION, EL USO DE LOS MISMOS MEDIOS DE PURIFICACION PARA TODOS LOS COMPONENTES HACE POSIBLE PURIFICAR CADA COMPONENTE CON ALTA EFICIENCIA Y UNA ALTA VELOCIDAD DE RECUPERACION, UN ASPECTO MUY VENTAJOSO PARA LA PRODUCCION INDUSTRIAL. TAMBIEN ES POSIBLE PRODUCIR EFICIENTEMENTE UNA VACUNA MEJORADA DE COMPONENTES DE PERTUSSIS PURIFICADOS QUE COMPRENDE UNA COMBINACION EFECTIVA DE HEMAGLUTININA FILAMENTOSA PERTUSSIS(FAH), PERTACTINA (PRN, 69K-OMP), PERTUSSIS FIMBRIOSA (FIM) Y TOXINA PERTUSSIS (PT)
ES95917474T 1994-04-28 1995-04-26 Metodo para separar componentes protectores de bordetella pertussis. Expired - Lifetime ES2136290T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP9156594 1994-04-28

Publications (1)

Publication Number Publication Date
ES2136290T3 true ES2136290T3 (es) 1999-11-16

Family

ID=14030044

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95917474T Expired - Lifetime ES2136290T3 (es) 1994-04-28 1995-04-26 Metodo para separar componentes protectores de bordetella pertussis.

Country Status (12)

Country Link
US (6) US6051240A (es)
EP (1) EP0755403B1 (es)
KR (1) KR100266556B1 (es)
CN (1) CN1147259A (es)
AT (1) ATE183194T1 (es)
AU (1) AU2352595A (es)
CA (1) CA2188424A1 (es)
DE (1) DE69511392T2 (es)
DK (1) DK0755403T3 (es)
ES (1) ES2136290T3 (es)
GR (1) GR3031481T3 (es)
WO (1) WO1995029934A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8910570D0 (en) 1989-05-08 1989-06-21 Wellcome Found Acellular vaccine
US6444211B2 (en) * 1991-04-03 2002-09-03 Connaught Laboratories, Inc. Purification of a pertussis outer membrane protein
EP1234580A1 (en) * 1995-05-04 2002-08-28 Aventis Pasteur Limited Acellular Pertussis Vaccines and Methods of Preparation Thereof
EP2430040A1 (en) 2009-05-11 2012-03-21 Novartis AG Antigen purification process for pertactin antigen
US8647640B2 (en) * 2009-06-24 2014-02-11 Richard E. COWART Vaccine compositions and methods of use to protect against infectious disease
CN102443572B (zh) * 2011-10-21 2012-12-19 武汉生物制品研究所有限责任公司 一种对脱毒后的百日咳疫苗抗原溶液进行纯化的方法
JP2018511655A (ja) * 2015-03-20 2018-04-26 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン ボルデテラ属に対するワクチン接種における使用のための免疫原性組成物
JP6993984B2 (ja) * 2016-03-29 2022-02-03 アンスティチュ パスツール ドゥ リール 変異ボルデテラ菌株および使用方法
CN108570098B (zh) * 2017-12-29 2021-09-07 武汉生物制品研究所有限责任公司 一种百日咳多种抗原成分的分离纯化方法
CN110358802B (zh) * 2019-08-16 2021-06-18 长春百克生物科技股份公司 一种去除百日咳组分菌毛蛋白2/3内毒素的方法
WO2022114921A1 (ko) * 2020-11-30 2022-06-02 주식회사 엘지화학 알루미늄 부형제를 이용하여 다가 혼합백신 내 백일해 균 유래 엔도톡신 제거 방법

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5750925A (en) * 1980-09-12 1982-03-25 Takeda Chem Ind Ltd Preparation of pertussis toxoid
US4729957A (en) * 1984-12-13 1988-03-08 The United States Of America As Represented By The Department Of Health And Human Services Process for manufacture of L-asparaginase from erwinia chrysanthemi
GB8512972D0 (en) * 1985-05-22 1985-06-26 Univ Glasgow Vaccine production
GB8601279D0 (en) * 1986-01-20 1986-02-26 Public Health Lab Service Purification of pertussis antigens
CA1337859C (en) * 1987-04-24 1996-01-02 Masashi Chazono Method for culturing bordetella pertussis, a pertussis toxoid and a pertussis vaccine
US5101019A (en) * 1987-05-22 1992-03-31 Takeda Chemical Industries, Ltd. Method for removing pertussis endotoxin, a pertussis toxoid and its production
GB8807860D0 (en) * 1988-04-05 1988-05-05 Connaught Lab Pertussis vaccine
US5101014A (en) * 1989-02-10 1992-03-31 United States Of America Process for the purification of a 69,000 da outer membrane protein of Bordetella pertussis
ES2084668T3 (es) * 1989-11-06 1996-05-16 Smithkline Beecham Biolog Procedimiento.
US5276142A (en) * 1989-12-11 1994-01-04 American Cyanamid Company Process for purification of a 69000 dalton antigenic protein from Bordetella pertussis
GB9007657D0 (en) * 1990-04-04 1990-05-30 Connaught Lab Purification of a pertussis outer membrane protein(omp69)
IT1248735B (it) * 1990-06-21 1995-01-26 Sclavo Spa Vaccini acellulari contro la pertosse
EP0484621A3 (en) * 1990-07-11 1992-08-26 American Cyanamid Company Efficacious vaccines against bordetella pertussis comprising a combination of individually purified pertussis antigens
ES2194841T3 (es) * 1991-11-15 2003-12-01 Pfizer Procedimiento de produccion de vacunas bacterianas gram negativas.
EP1234580A1 (en) * 1995-05-04 2002-08-28 Aventis Pasteur Limited Acellular Pertussis Vaccines and Methods of Preparation Thereof
US6696065B1 (en) * 1995-05-04 2004-02-24 Aventis Pastuer Limited Acellular pertussis vaccines and methods of preparation thereof

Also Published As

Publication number Publication date
KR970702874A (ko) 1997-06-10
US20020119161A1 (en) 2002-08-29
EP0755403B1 (en) 1999-08-11
DE69511392D1 (de) 1999-09-16
CA2188424A1 (en) 1995-11-09
DE69511392T2 (de) 2000-03-23
WO1995029934A1 (en) 1995-11-09
US20050180987A1 (en) 2005-08-18
US20090068228A1 (en) 2009-03-12
ATE183194T1 (de) 1999-08-15
DK0755403T3 (da) 2000-02-14
US20030133941A1 (en) 2003-07-17
AU2352595A (en) 1995-11-29
US20100055134A1 (en) 2010-03-04
US6051240A (en) 2000-04-18
CN1147259A (zh) 1997-04-09
EP0755403A1 (en) 1997-01-29
GR3031481T3 (en) 2000-01-31
KR100266556B1 (ko) 2000-09-15

Similar Documents

Publication Publication Date Title
ES2136290T3 (es) Metodo para separar componentes protectores de bordetella pertussis.
ES2165115T3 (es) Un procedimiento para la purificacion de fosfatidinilserina.
GT199900166A (es) Compuesto quìmico adecuado para usar como agente antiviral.-
PT95099A (pt) Processo para a preparacao de amino acidos ciclicos bem como dos seus intermediarios
NZ306009A (en) Medical database system, unique identifier assigned to files, machine readable version of identifier included in hard copies
ES2127184T3 (es) Un metodo para aislar y purificar a partir de bacterias proteinas receptoras de transferrina y lactoferrina, y la preparacion de vacunas que las contienen.
AR247372A1 (es) Procedimiento para purificar el agua efluyente de las instalaciones para fabricar urea.
ATE156187T1 (de) Verfahren zum reinigen von hepatits-a-virus (hav), so gereinigter virus und impfstoffzusammensetzungen, die ihn enthalten
PT879228E (pt) Processo para a preparacao de d-treo-(r,r)-metilfenidato e reciclagem de enantiomeros indesejaveis por epimerizacao
BR0011033A (pt) Métodos de purificação de dna e dna purificado
ATE92335T1 (de) Reinigung von keuchhustenantigenen.
ES2140652T3 (es) Uso de n-alquil-derivados de 1,5-didesoxi-1,5-imino-d-glucitol para el tratamiento de infecciones por el virus de la hepatitis b.
ES2134474T3 (es) Peptidos utilizados como agentes terapeuticos para el tratamiento de enfermedades autoinmunitarias.
ES2182827T3 (es) Gen del virus corona canino y usos del mismo.
ES2196157T3 (es) Oligonucleotidos especificos para el virus de la hepatitis c.
DE69001309D1 (de) Verfahren zur herstellung von antihaemophilem faktor (faktor viii), der eine hohe reinheit aufweist.
ATE395428T1 (de) Verfahren zur isolierung und reinigung von lipidezellwandkomponenten
TH20014A (th) วิธีการแยกส่วนประกอบป้องกันโรคไอกรนของ Bordetella pertussis
GB2007244A (en) Purifying Polyribosyl Ribitol Phosphate (PRP) and Vaccines containing Immunologically Active PRP
BR9712910A (pt) ra o tratamento de infecção por hiv
ATE241644T1 (de) Verfahren zur reinigung von tamm-horsfall- glykoprotein und uromodulin
ES2153982T3 (es) Derivados de piperidina disustituidos.
BR9608074A (pt) Processo para a produção e purificação de esteres cìclicos
KR960040378A (ko) 신증후출혈열 백신 및 그의 제조 방법
ATE74342T1 (de) Verfahren zur verminderung des anteils an ddtverwandten verunreinigungen in 1,1bis(chlorphenyl)-2,2,2-trichlor|thanol.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 755403

Country of ref document: ES